iBio (NYSE:IBIO) Trading Down 1%

Shares of iBio, Inc. (NYSE:IBIO) traded down 1% during mid-day trading on Wednesday . The company traded as low as $2.05 and last traded at $2.07. 124,709 shares changed hands during trading, a decline of 94% from the average session volume of 2,056,355 shares. The stock had previously closed at $2.09.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on IBIO shares. Chardan Capital restated a “buy” rating and issued a $5.00 price target on shares of iBio in a research note on Monday, June 3rd. StockNews.com began coverage on shares of iBio in a research report on Saturday, April 20th. They set a “sell” rating on the stock.

iBio Price Performance

The business’s fifty day moving average price is $2.13. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 0.04.

iBio (NYSE:IBIO) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.71) earnings per share for the quarter. As a group, equities research analysts anticipate that iBio, Inc. will post -99.82 EPS for the current year.

Institutional Investors Weigh In On iBio

A number of large investors have recently added to or reduced their stakes in the business. Lynx1 Capital Management LP purchased a new position in iBio during the first quarter worth $2,436,000. Ikarian Capital LLC acquired a new position in iBio in the 1st quarter valued at about $2,436,000. Finally, Opaleye Management Inc. purchased a new position in shares of iBio during the 1st quarter worth $2,761,000. 7.90% of the stock is owned by institutional investors and hedge funds.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.